Consortium for Clinical Research and Innovation, Singapore (CRIS)

Consortium for Clinical Research and Innovation, Singapore (CRIS)

Hospitals and Health Care

To nurture and build for Singapore, cutting edge capabilities and innovation in clinical research and translation.

About us

The Consortium for Clinical Research and Innovation, Singapore (CRIS) was established in 2020 with the goal of strengthening synergies and developing strategies for national-level clinical research and translation programmes that are under the stewardship of the Ministry of Health. It is a subsidiary of the Ministry of Health Holdings (MOHH). CRIS brings together six key national R&D initiatives and clinical services, and facilitate synergistic collaborations among them. These initiatives include: - Singapore Clinical Research Institute (SCRI) - National Health Innovation Centre Singapore (NHIC) - Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) - Precision Health Research, Singapore (PRECISE) - Singapore Translational Cancer Consortium (STCC) - Cardiovascular Disease National Collaborative Enterprise (CADENCE) CRIS aims to make a positive difference to Singapore patients and researchers by ensuring that these clinical research platforms and programmes are at the cutting edge of capability development and innovation. This will be achieved through facilitated collaborations and enduring partnerships with research and biomedical entities and communities across the public sector and industry across Singapore.

Website
http://www.cris.sg
Industry
Hospitals and Health Care
Company size
51-200 employees
Headquarters
Singapore
Type
Government Agency
Founded
2020

Locations

Employees at Consortium for Clinical Research and Innovation, Singapore (CRIS)

Updates

  • 🔎🧫 Are you a healthcare professional interested in exploring the expanding field of cell therapy or keen to transition into regulatory, business, or quality roles in cell therapy research and development? 📋 Register for the Professional Certificate in Application of Immune Effector Cells in Cell Therapy jointly offered by ACTRIS and NUS!

    Open for Registration! Jointly offered by NUS Microbiology and Immunology and Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), we’re excited to announce the third intake of the NUS Professional Certificate in Application of Immune Effector Cells in Cell Therapy. The certificate programme is offered in both synchronous and asynchronous formats.  📈 Programme Highlights:  • Examine key considerations in clinical research for cell therapy  • Gain comprehensive insights into quality control and assurance for manufacturing and patient application of cell-based therapies  • Discover the process and essential steps of Chimeric Antigen Receptor (CAR) T-cell treatments  • Understand regulatory implications for CAR T-cell therapies and their influence on cell therapy practices 🎓 Who Should Attend: • Biomedical graduates transitioning into regulatory, business, or quality roles in cell therapy research and development • Healthcare professionals interested to explore the expanding field of cell therapy and its applications. 🗓️ Registration Deadline:  Registration closes on 22 Jan 2025 Transform tomorrow’s therapies and elevate your expertise in this pioneering field 🧬. Learn more and register via: https://lnkd.in/gjQYn6at

    Professional Certificate in Application of Immune Effector Cells in Cell Therapy (Synchronous & Asynchronous) - NUS Medicine

    Professional Certificate in Application of Immune Effector Cells in Cell Therapy (Synchronous & Asynchronous) - NUS Medicine

    https://medicine.nus.edu.sg

  • 🎉 𝐂𝐀𝐃𝐄𝐍𝐂𝐄 𝐚𝐧𝐝 Medera Inc. 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐝 𝐀𝐬𝐢𝐚’𝐬 𝐟𝐢𝐫𝐬𝐭 𝐦𝐮𝐥𝐭𝐢-𝐜𝐞𝐧𝐭𝐫𝐞 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 Our programme, Cardiovascular Disease National Collaborative Enterprise (CADENCE) and Medera, have initiated a ground-breaking clinical trial for a novel gene therapy product aimed at treating heart failure. This trial marks the first collaboration between Singapore's two national heart centres (National Heart Centre Singapore and NUHCS - National University Heart Centre, Singapore), and with Tan Tock Seng Hospital. This is a testament to the country’s robust cardiovascular research infrastructure. It also highlights CADENCE’s efforts in streamlining clinical trial processes across these institutions. This includes streamlining contracting procedures, simplifying the costs of conducting cardiovascular clinical trials across these sites, as well as providing a centralised point of-contact for companies looking to conduct clinical trials and bring novel therapies to Singapore. "The launch of the SRD-001 trial in Singapore is a landmark moment for cardiovascular cell and gene therapy research in Asia. It underscores our commitment to integrate cutting-edge research and technologies to combat cardiovascular diseases. By bringing together the best of our national research capabilities and expertise, we aim to pave the way for innovative treatments that can significantly improve patient outcomes. This trial not only highlights Singapore’s position as a leader in cardiovascular research but also showcases our potential to contribute to the global fight against heart failure,” said Prof Derek Hausenloy, Executive Director, CADENCE. Read more: https://lnkd.in/gVZ2A6Vi Danny Soon Roger Hajjar Ronald Li Shiva Singh

    CADENCE and Medera launch Asia’s First Multi-Centre Gene Therapy Trial in Singapore for Heart failure

    CADENCE and Medera launch Asia’s First Multi-Centre Gene Therapy Trial in Singapore for Heart failure

    biospectrumasia.com

  • Congratulations to programme leads from CADENCE and PRECISE on your recent research accolades! Professor Derek Hausenloy from our programme, Cardiovascular Disease National Collaborative Enterprise (CADENCE) was among ten Duke-NUS clinician-scientists and researchers, who were recognised for their cross-field contributions by Clarivate in the company’s latest ranking. The Highly Cited Researchers list, curated by Clarivate identifies individuals who have demonstrated significant and broad influence in their field or fields of research. Professor Patrick Tan, Executive Director of our programme, Precision Health Research, Singapore (PRECISE) was also among 66 researchers from across the SingHealth Duke-NUS Academic Medical Centre (AMC) who was also featured in the 2024 Stanford World’s Top Scientists list: career-long impact category, in recognition of his commitment to nurturing clinician-scientists across career stages. Read more here: https://lnkd.in/giM8eVqh? #CRISCelebrates #cardiovascularresearch #npm_sg

    View organization page for Duke-NUS Medical School, graphic

    34,369 followers

    Congratulations to the 10 SingHealth Duke-NUS Academic Medical Centre (AMC) clinician-scientists and researchers who were named Clarivate's Highly Cited Researchers for 2024! In addition to making the Clarivate ranking, 97 clinician-scientists and researchers from the School and the SingHealth Duke-NUS AMC were ranked in the 2024 Stanford World’s Top 2% Scientists list published by Elsevier on 16 September 2024. Read more about their achievements and work from the link in comments. #DukeNUS #Research #HighlyCited2024 SingHealth

    • No alternative text description for this image
  • On 9 November 2024, Tan Tock Seng Hospital hosted an outreach event, “Life with a Genetic Kidney Disease: Patient and Family Support Day”, which gathered about 35 participants. Organised by RAPIDS (Renal Alliance for PrecIsion Diagnosis in Singapore), presenters shared their insights on managing chronic kidney disease, navigating genetic testing, and accessing emotional support. The presentations provided invaluable support for individuals and families impacted by genetic kidney conditions. This event was supported by our programme, Precision Health Research, Singapore (PRECISE), as part of the Clinical Implementation Pilot (CIP) for kidney diseases, which is led by clinical co-PI, A/Prof Kar Hui Ng, National University Hospital (NUH). Adj Assoc Prof See Cheng Yeo, HOD and Senior Consultant, Renal Medicine, TTSH, opened the event by sharing about the myths of genetic kidney diseases. He also shared about the importance of patients’ voices that would help healthcare professionals to support and manage them better. Dr Cynthia Lim, Senior Consultant, Renal Medicine, Singapore General Hospital (SGH) shared about chronic kidney disease stages, stressing the importance of early diagnosis and risk factors for developing the condition. Dr Irene Mok, Senior Consultant, Renal Medicine, SGH shared insights on Alport Syndrome and genetic kidney diseases, covering types, treatments, and prognosis. Ms Sylvia Kam, Senior Genetic Counsellor, Genetics Service, KK Women's and Children's Hospital, discussed the risks and limitations of genetic testing, empowering participants with the knowledge to make informed decisions about their options. Dr Gek Cher Chan, Consultant, Division of Nephrology, NUH, delved into the potential benefits of genetic testing and outlined the steps involved to make informed decisions. Dr Ru Sin Lim, Consultant, Renal Medicine, TTSH and site PI at TTSH for the PRECISE CIP for kidney disease, addressed the emotional challenges faced during the process of genetic testing and offered strategies to help patients cope. One of Dr Ru Sin’s patient shared about his personal experience of being diagnosed with a genetic kidney condition. He shared about how he coped with his daily life since young and how he felt when he was told that he had a genetic condition. His positive attitude towards life truly inspired the audiences. The CIP in Primary Glomerular Diseases is one of five clinical implementation pilots by PRECISE, which looks to facilitate the incorporation of genetic and genomic testing into clinical pathways to improve patient outcomes while maintaining cost-effectiveness and optimising the healthcare experiences for healthcare providers and patients. Find out more about the CIPs: https://npm.sg/cip Jun Li Ng Ziyin Wang John Tan Irenaeus Chia #precisionmedicine #genetictesting #kidneyhealth #innovation #npm_sg #AIportSyndrome #PaediatricNephrology #Adultnephrology

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +8
  • 🌏 Singapore-Sweden Healthcare Symposium: Empowering Innovation in Healthcare 🌟 On 20 Nov, our programmes, Precision Health Research, Singapore (PRECISE) and National Health Innovation Centre Singapore (NHIC) participated in the Singapore-Sweden Healthcare Symposium. 🌟 Sweden’s First Lady of the Court, Ms Anna Hamilton, represented Her Majesty Queen Silvia, together with State Secretary for Healthcare, Sweden, Ms Miriam Söderström, and Singapore’s Minister for Health, Mr Ong Ye Kung, opened the forum with inspiring remarks on advancing healthcare through innovation and collaboration, marking 58 years of partnership between Singapore and Sweden and setting the stage for deeper collaboration. Minister Ong emphasised the importance of international cooperation to address complex healthcare needs such as ageing populations, chronic diseases, and how Singapore is taking proactive steps to build capabilities in precision medicine, genomics and AI. He also highlighted Singapore and Sweden’s shared DNA of embracing technology and innovation, which led to groundbreaking collaborations in cancer research, biopharmaceutical manufacturing and entrepreneurship. 💡 Prof Patrick Tan, Executive Director of PRECISE, shared how PRECISE engages with stakeholders and ecosystem partners to advance research and translation of precision medicine in Singapore. He also moderated a panel discussion 'Precision health and healthy ageing: How can we transform healthcare?', with panellists Dr Laurent Leksell, Ms Suyeon Kim, Mr Anders Brinne and Assoc Prof Reshma Merchant. The panel delved into insightful discussions on the value of early screening, advanced diagnostics and biomarker-driven treatments in supporting healthcare affordability in the long-term and highlighted potential areas of collaboration in precision medicine between the two nations. 💡 Empowering innovation in healthcare: Dr Pauline Erica Tay, Director, National Health Innovation Centre (NHIC), together with Dr Britta Stenson, PhD, Dr Boubou Hallberg, Dr Lisa Ang, Dr Hans Grönlund and Ms Anna Salström, shared valuable insights on leveraging the potential of innovation in healthcare. The panel also discussed the integration of AI and digital health solutions and the role of innovation agencies and governments in supporting startups. The event also included a Memorandum of Understanding (MoU) signing ceremony between Singapore and Sweden, which marked a renewed commitment to driving healthcare transformation together. A second MoU was also signed between the National University Health System, Sahlgrenska University Hospital, AstraZeneca, Ericsson and Business Sweden to establish a global health innovation network. The informative sharing by the presenters and panellists reflected the value of mutual learning and the importance of innovation and collaboration. With aligned visions and shared expertise, Singapore and Sweden are paving the way for resilient, future-ready healthcare systems. #npm_sg

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +4
  • ICYMI: 🎉 Congratulations again to National Health Innovation Centre (NHIC)! Cheers to another decade of driving impactful healthcare innovations, collaboration, and transformative change. #CRIScelebrates

    🌟14 November marked a significant milestone as NHIC celebrated a decade of providing strong support to public healthcare institutions in enabling the translation and commercialisation of clinical innovations to address unmet clinical needs in Singapore and beyond. Guest of Honour, Dr Janil Puthucheary, Senior Minister of State, Ministry of Digital Development and Information and Ministry of Health (Singapore), graced the appreciation dinner together with close to 300 thought leaders, clinician innovators, scientists and start-up founders — each who has played a pivotal role in shaping the future of healthcare and medtech innovation landscape. Four local enterprises — Biobot Surgical, Doctor Anywhere, Lucence, and Mirxes that have forged strong partnerships with healthcare institutions to implement new technologies to scale received NHIC's Rising Star Healthcare Innovation Tributes. They have exemplified dedication in advancing patient care through innovation and significant contribution to the broader economy. “As we look to the future, we are eager to build upon our accomplishments, advancing further in healthcare technology development and remaining steadfast in our commitment to driving systems-level healthcare transformation forward,” said A/Prof Henry HO, Executive Director, NHIC. NHIC is poised to support innovations further through an expansion of its funding schemes, where high potential projects from local public healthcare institutions can receive additional project funding and other support from NHIC towards clinic and market readiness. The evening also featured a special Recognition and Appreciation Tribute accorded to our founding chairman, Prof K. Ranga Rama Krishnan, MB, ChB whose visionary leadership was instrumental in NHIC's establishment and expansion into a decade of impactful achievements. A commemorative e-book, “A Decade of Forging Healthcare Innovation and Beyond”, was also launched. The e-book features inspirational healthcare innovations supported by NHIC, and other unique initiatives spearheaded by the local healthcare ecosystem. 📖 View the e-book here: https://for.sg/nhic-ebook The appreciation dinner ended on a high note as we celebrated with our partners our shared journey and renewed commitment to improving patient outcomes and spearheading solutions to meet today’s healthcare challenges. Our full press release is available at https://lnkd.in/gtfb6G45 🥳 Here’s to another decade of driving impactful healthcare innovations, collaboration, and transformative change! #NHIC10 #aDecadeofHealthcareInnovation #aDecadeofHealthcareCommercialisation

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +15
  • 14 November was World Diabetes Day. With increasing prevalence of diabetes in Singapore, digital innovations and ongoing research can help people living with diabetes manage better.  In this commentary piece, A/Prof Danny Soon, CEO, CRIS and Executive Director, Singapore Clinical Research Institute (SCRI), highlights the significant technology advancements and research efforts that have empowered patients and their caregivers. “We can enhance diabetes management with technology to enable more targeted, personalised, and even preventive care, and better empower individuals in their care journey. Research also plays a crucial role in deepening our understanding of the patient journey, including challenges such as medication compliance, care delivery and predictors of health outcomes.” A/Prof Soon further highlights the potential of how collaborative and concerted effort by professionals in healthcare across public and private sectors can bring about innovations that can transform diabetes care and make an impact on the lives of patients and loved ones. Click here to read more: https://lnkd.in/gJ6BHdNh       Singapore Clinical Research Institute (SCRI) National Health Innovation Centre (NHIC) #WorldDiabetesDay #DiabetesCare #Innovation #HealthcareResearch #HealthTech #AI #DiabetesManagement

    Science Talk: Helping people manage diabetes through technology and research

    Science Talk: Helping people manage diabetes through technology and research

    straitstimes.com

  • ✨Last week, CRIS held its Dinner & Dance, themed “Party like a Popstar” and it was truly a night to remember! 🤩 Everyone arrived decked out in glitz and glamour. Staff from across our programmes showcased their creativity through energetic dance numbers, grooving to the beat of iconic pop hits from the 1980s to current music chart favourites. CRIS CEO, A/Prof Danny Soon, along with the DnD working committee, began the event with an opening item to the tunes of a popular magic song number (no prizes for guessing the title of this popular song), and CEO performed an Elton John favourite! Talents and ‘Pop Stars’ from CRIS HQ and our programmes ACTRIS, STCC, NHIC and SCRI took centre stage in song / dance performances. In addition, interactive games filled the room with laughter. Prizes were aplenty, from award trophies for our best dressed and best performing groups, to a digital ‘spin the wheel’ lucky draw which duly picked winners all evening. A memorable piece was SCRI’s performance, which rallied over 40 pop stars in a six-min dance medley ranging from classic 80s and 90s Cantopop to endearing K-pop-style synchronised steps. The night wrapped up with everyone on the dance floor for a high-energy finale! 🎉 #CRISDinnerAndDance #CRIScelebrates Singapore Clinical Research Institute (SCRI) National Health Innovation Centre (NHIC) Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +15
  • Consortium for Clinical Research and Innovation, Singapore (CRIS) reposted this

    As we commemorate our 1️⃣0️⃣ Year Anniversary, we are excited to recognise promising #homegrown #enterprises whose #innovations have positively impacted the healthcare sector over the last decade 🎊 The Innovation Tributes 🏆 will recognise: 🚀 Outstanding achievements of local healthcare innovation and enterprises and celebrate their strong contributions to #healthcareadvancement locally and globally. 🤝 Public-private #partnerships that have made significant strides in advancing medical technologies and solutions, ultimately improving patient care and #healthimpact while contributing to #economicoutcomes. The recipients will be announced this November at the Anniversary Dinner, 📣 stay tuned! Special thanks to Enterprise Singapore EDBI Pte Ltd Temasek Foundation and the MOH Holdings Pte Ltd (Singapore) for their participation as part of the evaluation panel. #NHIC10 #aDecadeofHealthcareInnovation #aDecadeofHealthcareCommercialisation National Health Innovation Centre (NHIC) Consortium for Clinical Research and Innovation, Singapore (CRIS)

    • No alternative text description for this image

Affiliated pages

Similar pages